H Company Launches Next-Generation Autonomous AI Agents for Enterprise and Consumer Markets
Article content
Article content
Article content
H Company launches its next-generation European agent suite, comprising Runner H, Tester H, and Surfer H, and the open-sourcing of Holo-1 H, its cutting-edge visual-language model, lays the foundation for the next era of autonomous intelligence and artificial superintelligence.
Three products reflect H Company's vision to make a trusted, action-oriented AI that delivers task execution beyond traditional chatbots, achieving a 92.2% success rate, the state-of-the-art in computer-use technology while reducing costs by up to 5.5x against peers (OpenAI, Anthropic, Google).
The three AI agents cover task execution, web navigation and quality assurance, delivering faster task completion, GDPR-first data handling, and seamless hand-offs across the H-platform.
Article content
PARIS — H Company, a leading European AI Research and Product company backed by $220 million from tier-one investors, today announced the public launch of its autonomous AI agent platform featuring three specialized agents built to carry out complex digital tasks with human-in-the-loop.
Article content
The launch includes:
Article content
Runner H™, an orchestration platform for multi-step task completion,
Surfer H™, a web-native agent for browser-based automation,
Tester H™, an enterprise solution for automated software testing.
Article content
The company simultaneously open-sourced Holo-1, its proprietary visual-language model, in partnership with Hugging Face, Nvidia (NIM soon available) and AWS (Amazon).
Article content
H Company's current product selection supports its aim of making trusted, action-oriented AI agents available to organizations of all sizes. H Company's agents, which are built on proprietary multimodal models, bridge the gap by combining planning and vision capabilities to deliver measurable business outcomes.
Article content
'We are witnessing the transition from conversational AI to execution intelligence,' said Charles Kantor, Co-founder and Chairman of H Company. 'Entering the era, where agents don't just assist—they complete entire workflows autonomously, delivering the productivity gains enterprises have been seeking from AI investments.'
Article content
Runner H serves as H Company's flagship orchestration platform, delivering 'intelligence in motion' by enabling users to accomplish complex, multi-step objectives through a single natural language prompt and is now available to the public.
Article content
Runner H dynamically coordinates specialized sub-agents and integrates with existing enterprise applications (including MCPs and agnostic interactions proprietary and additional agents), supporting seamless workflows across web browsers, document systems, and business applications while maintaining cost-effectiveness at scale.
Article content
Surfer H
Article content
Surfer H operates as a web-native automation agent, navigating browser environments with human-like precision while delivering cost-effective automation solutions. Unlike API-dependent solutions, Surfer H interacts directly with web interfaces, enabling deployment across any website without custom integrations or compatibility requirements, creating a powerful, general-purpose, cost-effective web automation system.
Article content
Tester H
Article content
Tester H addresses enterprise software testing challenges by converting natural language test scenarios into executable automated testing protocols. The platform supports both web and mobile applications, enabling teams to scale quality assurance processes without expanding technical testing resources.
Article content
Proven Performance Metrics
Article content
Benchmark testing demonstrates H Company's agents deliver superior cost-performance ratios and optimal value propositions compared to existing market solutions:
Article content
Surfer H achieved 92.2% task completion accuracy on the WebVoyager benchmark at just $0.13 per task, establishing the strongest tradeoff between accuracy and cost.
Performance exceeds that of major technology providers while reducing operational costs by up to 10 times, setting the Pareto frontier for performance-per-dollar.
Holo-1 visual-language model achieves 76.2% UI localization accuracy with affordable inference costs, leading performance among models under 7B parameters (the highest small-size model overall).
Article content
H Company's release of Holo-1 under Apache 2.0 licensing enables developers and enterprises to build production-ready custom automation solutions using visual AI capabilities. The model delivers commercial-grade accuracy for UI understanding and interaction.
Article content
The open-source initiative includes the WebClick dataset, featuring 1,639 real-world UI interaction scenarios designed to advance industry-wide development of visual AI applications.
Article content
Market Availability and Enterprise Adoption
Article content
Runner H is immediately available for public access, in waves, while Tester H targets enterprise customers requiring automated software testing capabilities. The platform's browser-based agent, Surfer H, ensures compatibility with existing enterprise privacy requirements, addressing key concerns for large-scale organizational deployment.
Article content
H Company is a next-generation AI research and product company pioneering the future of autonomous, agentic AI. Founded to build intelligence that acts—not just reacts—H Company is creating the foundational infrastructure for autonomous AI systems that drive real-world outcomes across industries. With $220 million in funding, H Company is backed by leading global investors including Accel, Eric Schmidt and Yuri Milner.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Billionaire Stanley Druckenmiller Sold Palantir and Amazon and Is Piling Into This Artificial Intelligence (AI) Stock Instead
Back in 2022, billionaire Stanley Druckenmiller made a sizable bet on chipmaker Nvidia. The company has gone on to become one of the biggest winners of advancements in generative AI, for which its graphics processing units (GPUs) are well suited. Druckenmiller has also been an investor in Palantir Technologies (NASDAQ: PLTR), which has used AI to improve its software and expand its market. Druckenmiller has also made a lot of money by investing in Amazon (NASDAQ: AMZN) throughout his career, taking advantage of the cloud computing leader's growth. But Druckenmiller is shifting his attention and his money away from these AI giants. He sold out of Nvidia about a year ago (although he says he regrets that decision). In the first quarter, he got rid of his remaining shares of Palantir and trimmed his Amazon investment by more than half. In their place, he's buying a different company that stands to benefit from continued spending on AI development but whose stock looks undervalued. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Why Druckenmiller is selling Palantir and Amazon Both Amazon and Palantir are producing strong results as enterprise customers spend heavily on AI software and development. Palantir has seen its U.S. commercial business take off thanks to its Artificial Intelligence Platform (AIP). Businesses are expanding their use cases for AIP, and the service is reducing the need for clients to hire new workers. That has helped Palantir grow revenue extremely quickly without much overhead, resulting in strong earnings growth. Amazon remains the largest public cloud platform in the world with Amazon Web Services (AWS). The company is seeing strong demand for AI services on AWS, and it's spending as quickly as it can to meet that demand, including plans to pour over $100 billion into capital expenditures (mostly for AWS) in 2025. The operating margin for AWS has soared to nearly 40%, pushing Amazon's operating profits considerably higher. But Druckenmiller's decision to reduce his stake in these companies seems to be based purely on valuation. Indeed, Palantir is one of the most expensive stocks on the market trading at over 75 times management's 2025 revenue outlook. Druckenmiller has also traded in and out of Amazon stock based on price, and shares reached an all-time high of more than $240 per share last quarter. With all that in mind, it appears Druckenmiller has found a suitable replacement in the AI space that offers exceptional value at its current price. Here's the AI stock Druckenmiller is piling into With hyperscalers like Amazon committing to investing billions of dollars per year in AI data centers, the growth in AI spending seems to be far from over. One company stands behind practically all of the silicon chips you'll find in those data centers: Taiwan Semiconductor Manufacturing (NYSE: TSM), or TSMC. TSMC is the leading chip manufacturer in the world, commanding a dominant share of the market. Its lead is cemented by the best-in-class technology required for making the most cutting-edge chips. That's why companies like Nvidia choose TSMC to print and package its chips. Using another manufacturer would likely result in a higher cost with an inferior product. TSMC benefits from a virtuous cycle. It's the largest chip manufacturer in the world, which means it brings in a ton of revenue. It can, therefore, invest more in research and development and capital expenditures to maintain its technological lead and ensure enough capacity to meet growing demand. That, in turn, brings in more revenue. That said, chip fabrication is a capital-intensive, cyclical business. If demand falls, TSMC is still responsible for maintaining its expensive equipment, even if it's not producing as many chips. The good news for investors is that TSMC also expects strong growth in AI spending through the end of the decade. Management believes AI-related revenue will double this year, and the company could produce a compound annual growth rate of close to 40% for AI chips through 2029. Overall, management is guiding for 20% compound annual growth for the entire business. Revenue is up over 43% year over year through the first four months of 2025. Despite the potential for strong revenue growth over the next five years with excellent gross and operating margin profiles, the stock trades for less than 21 times forward earnings estimates. There's a reason to discount the stock somewhat, given the ongoing global trade war launched by the Trump Administration and the geopolitical risk surrounding Taiwan. But the current valuation still looks extremely attractive for investors, and Druckenmiller seems to agree. Druckenmiller tiptoed into the stock in the second half of last year, investing about $20 million, but he more than quintupled his investment in the first quarter, making it one of his biggest holdings. With TSMC's share price sitting around where it started the year, there is still an opportunity to join Druckenmiller with an investment in TSMC. Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now? Before you buy stock in Taiwan Semiconductor Manufacturing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adam Levy has positions in Amazon and Taiwan Semiconductor Manufacturing. The Motley Fool has positions in and recommends Amazon, Nvidia, Palantir Technologies, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.
Globe and Mail
9 hours ago
- Globe and Mail
Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's 'Retinal Vein Occlusion Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Retinal Vein Occlusion Pipeline. Dive into DelveInsight's comprehensive report today! @ Retinal Vein Occlusion Pipeline Outlook Key Takeaways from the Retinal Vein Occlusion Pipeline Report In May 2025, Bayer conducted a study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease. In May 2025, EyeBiotech Ltd announced a Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD). DelveInsight's Retinal Vein Occlusion Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Retinal Vein Occlusion treatment. The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Promising Retinal Vein Occlusion Pipeline Therapies such as Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Stay ahead with the most recent pipeline outlook for Retinal Vein Occlusion Treatment. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinal Vein Occlusion Treatment Drugs Retinal Vein Occlusion Emerging Drugs Profile KSI-301: Kodiak sciences The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen. 601: Sunshine Guojian Pharmaceutical 601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials. IBE-814: Ripple Therapeutics IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO). The Retinal Vein Occlusion Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment. Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion Market Explore groundbreaking therapies and clinical trials in the Retinal Vein Occlusion Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Retinal Vein Occlusion Drugs Retinal Vein Occlusion Companies Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical. Molecule Type Retinal Vein Occlusion Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Retinal Vein Occlusion Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Retinal Vein Occlusion Market Drivers and Barriers Scope of the Retinal Vein Occlusion Pipeline Report Coverage- Global Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion Pipeline Therapies- Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Retinal Vein Occlusion Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Retinal Vein Occlusion Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Retinal Vein Occlusion: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) KSI-301: Kodiak sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) 601: Sunshine Guojian Pharmaceutical Drug profiles in the detailed report….. Early Stage Products (Phase I) MHU650: Novartis Drug profiles in the detailed report….. Inactive Products Retinal Vein Occlusion Key Companies Retinal Vein Occlusion Key Products Retinal Vein Occlusion- Unmet Needs Retinal Vein Occlusion- Market Drivers and Barriers Retinal Vein Occlusion- Future Perspectives and Conclusion Retinal Vein Occlusion Analyst Views Retinal Vein Occlusion Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
9 hours ago
- Globe and Mail
ChargePoint (CHPT) Q1 2026 Earnings Transcript
DATE Wednesday, June 4, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Rick Wilmer Chief Financial Officer — Mansi Khetani Need a quote from one of our analysts? Email pr@ TAKEAWAYS Total Revenue: $98 million for Q1 FY2026, in line with company guidance. Non-GAAP Gross Margin: 31%, a non-GAAP improvement of one percentage point sequentially and seven percentage points year over year (non-GAAP). SaaS Subscription Gross Margin: Achieved a record 60% on a GAAP basis. Adjusted EBITDA Loss: $23 million non-GAAP adjusted EBITDA loss, compared with a $17 million loss in the prior quarter and a $36 million loss in the first quarter of last year. Network Charging Systems Revenue: $52 million, representing 53% of total revenue, almost flat sequentially despite Q1 typically experiencing a seasonal dip and down 20% year on year. Subscription Revenue: $38 million in subscription revenue, or 39% of total revenue, essentially flat sequentially and up 14% year on year. Other Revenue: $8 million, or 8% of total revenue, down 31% sequentially and down 8% year on year, mainly due to lower one-time project revenue. Geographic Mix: North America represented 85% of revenue, and Europe was 15%, with European revenue down mainly due to weakness in Germany. Billings Mix by Vertical: Commercial 71%, fleet 13%, residential 12%, and other 3%. Inventory: Inventory balance increased by $3 million due to FX impacts, but inventory units decreased across most products as sell-through continued. Ending Cash Balance: $196 million in cash on hand, with access to a $150 million undrawn revolving credit facility. Charging Ports Under Management: Over 352,000 total under management, including more than 35,000 DC fast chargers and over 122,000 ports in Europe. Roaming Partnerships: Enabled access to more than 1.25 million charging ports globally. New Product Announcements: Introduction of a theft-resistant charging cable and a new AC hardware architecture, with the latter targeting lower cost and improved margins. Eaton Partnership: Announced collaboration with Eaton to deliver integrated EV charging and power management solutions, with initial co-developed products set for announcement in September. Q2 Revenue Guidance: Expected revenue in the range of $90 million to $100 million. Operational Focus: Continued emphasis on gross margin expansion, cost management, and achieving adjusted EBITDA positivity in a quarter during FY2026. SUMMARY ChargePoint Holdings, Inc. (NYSE:CHPT) reported first-quarter revenue that matched internal expectations, highlighting stable top-line performance despite ongoing macroeconomic and policy headwinds. Management stated that new integrated solutions from the Eaton partnership are now available for order, and further product innovations are scheduled for announcement in September, aiming to bolster incremental revenue growth and differentiation. The company confirmed that new AC hardware will launch at a competitive price to support both US and European expansion, with rollout of the new architecture planned over the next year and the first model targeted for production in July. Wilmer said, "We still expect non-GAAP margin improvement later in FY2026." emphasizing that anticipated US tariffs will have only a minimal cost impact due to effective mitigation actions. Management highlighted US and European EV sales grew 16% and 22%, respectively, in Q1, positioning infrastructure utilization as a positive demand signal for future industry expansion. Wilmer stated that voluntary industry exits and increased regulatory scrutiny on competitors create "a meaningful opportunity for ChargePoint Holdings, Inc. to gain market share." Khetani remarked that "inventory balance will reduce gradually throughout the year, helping to free up cash." A more significant decrease is anticipated in the second half as revenue increases. INDUSTRY GLOSSARY CPO: Charge Point Operator, an entity responsible for managing and maintaining EV charging infrastructure. V2X: Vehicle-to-Everything, a technology enabling electric vehicles to exchange power or information with the grid, buildings, and other systems. AC Hardware Architecture: Alternating Current charging system design, indicating the product and platform structure for AC chargers as opposed to Direct Current (DC) fast chargers. ATM: At-the-Market offering, a program allowing companies to sell shares into the open market over time. Full Conference Call Transcript Rick Wilmer: Good afternoon, and welcome to ChargePoint Holdings, Inc.'s first quarter fiscal 2026 earnings call. Today, I will walk you through key results for the quarter, provide insights into recent market and policy developments, and highlight the progress we have made on our two major priorities for the year: delivering innovation and driving growth. In addition, I will cover two significant announcements that directly support these priorities and positively influence ChargePoint Holdings, Inc.'s path to achieving positive non-GAAP adjusted EBITDA in a quarter of this fiscal year. Let's begin with our Q1 financial results. Revenue for the first quarter came in at $98 million, right within our guidance range. Non-GAAP gross margin continues to increase quarter over quarter, reaching a new high of 31%. Notably, our SaaS subscription gross margin climbed to a record 60%, underscoring the strength of our SaaS-focused business model. We built momentum across the business in Q1. Our DC fast charging program with General Motors has been a success, with the pace of site openings accelerating and over 500 additional ports signed off by GM for deployment. We extended multiple agreements with Mercedes-Benz, reinforcing our long-term relationship. Our theft-resistant charging cable was met with strong market interest and will go into production this summer for our own hardware models. Deenergized, our software management solution for CPOs, is now actively managing over 700 charger models from over 85 different vendors of charging hardware. This is a testimonial to the scale of our third-party hardware integrations. In total, ChargePoint Holdings, Inc. now has over 352,000 ports under management, of which more than 35,000 are DC fast chargers, and more than 122,000 are located in Europe. With our roaming partnerships, we enable access to more than 1.25 million charging ports globally. Our business is proving to be resilient on the top line despite US macroeconomic conditions and market uncertainty, as well as the bottom line through the cost and operational actions we took last year. Looking ahead regarding US tariffs on our products, expect only a minimal increase in the cost of goods sold. Also, expect cost reductions to exceed the impact of the current tariffs. Therefore, we still expect margin improvement later in the year. The limited impact reflects the swift and effective execution of our mitigation plan. We see positive momentum on two fronts: one, EV adoption, and two, utilization rates. EV adoption continues on a steady upward trajectory, a trend which has held for more than a year. Despite political turbulence dampening consumer and capital spending, North American EV sales were up 16% year over year for Q1 according to Rimotion. In Europe, EV momentum rebounded strongly with the same data set reporting 22% EV sales growth year over year for Q1, a significant surge. The European Green Deal mandates all new cars sold there be zero emission by 2035, reinforcing the EU's trajectory of EV adoption. All of this forms a strong leading indicator for the charging industry. The trends we observed last quarter remain intact. The market is actively planning and inquiring, but widespread purchasing is being impacted by economic uncertainty. Inevitably, with more EVs on the road, existing infrastructure is under mounting pressure. A recent report by Perin Data concluded that many US cities are approaching maximum charge utilization during peak hours, with five major markets past or approaching a staggering 40% utilization rate. This strain is a positive signal for our customers who monetize charging, but it is a growing concern for EV drivers facing long waits at occupied stations. We believe this will lead to the installation of more chargers, and ChargePoint Holdings, Inc. will be ready to capitalize on that demand. Despite the growth to come, the market has recently seen attrition and the voluntary exit of major players, even Chinese competitors coming under the scrutiny of the federal government. These developments, while natural for a new industry at our stage, create a meaningful opportunity for ChargePoint Holdings, Inc. to gain market share. We are not waiting for the growth to come to us; we are actively pursuing it. This brings me to the most exciting announcement of the year so far: our new partnership with Eaton, one of the world's largest intelligent power management companies. The cornerstone of this partnership is innovation, which will drive growth. Our goal is to make electrified transportation simple and economically a no-brainer. Charging deployments are increasingly complex, with a significant portion of them requiring grid upgrades. So we are integrating charging and electrical equipment into a single solution which addresses a major gap in the market. Together, ChargePoint Holdings, Inc. and Eaton will deliver EV charging, electrical infrastructure, energy management, and engineering services as the market's only end-to-end EV charging and power management solutions. These fully integrated solutions will get our customers up and running faster, simultaneously lowering their costs, and are available for order now. The next phase of the partnership will offer co-developed future technologies to further drive down costs, improve efficiency, and advance bidirectional power flow technology to fully optimize V2X capabilities. This will enable customers to use EVs as another distributed energy resource they can integrate into their energy infrastructure to help power operations. The first innovations from this effort are set to be announced in September. So what does this do for ChargePoint Holdings, Inc.'s business? In addition to a compelling and highly differentiated offering, we now have access to Eaton's formidable go-to-market engine, which does nearly $25 billion in annual sales across more than 160 countries. We anticipate that the relationship will drive incremental revenue growth for ChargePoint Holdings, Inc. This partnership cements ChargePoint Holdings, Inc. as the enabler of the entire EV ecosystem, from the grid to the dashboard of the vehicle and everything in between. Our second major announcement of the quarter, once again aligned with our goal of delivering innovation, was the announcement of our new AC hardware architecture. This is the first product line developed utilizing our lower-cost co-development structure and will enter the market at a highly competitive price point while still increasing our margins. This new architecture underpins a range of upcoming models that will roll out over the next year, serving home, commercial, and fleet use cases. These products will represent a major portion of our hardware volume. By bringing a generational leap in our technology to market at an affordable price point, we anticipate greater volume in the US, where we have the number one AC market share and considerable market penetration in Europe, where we have not had a product in this category to date. The first charger, part of our European take-home fleet solution, is expected to begin production in July. Growth and innovation remain the year two priorities of our strategic plan, and we are making progress on both. We entered year two ahead of schedule, positioning us to realize the benefits of our streamlined cost structure and revitalized product portfolio in year three. Our partnership with Eaton unlocks immediate growth opportunities by combining our EV charging leadership with their complementary solutions and their commercial scale. Our new AC hardware architecture is the first of several high-impact innovations planned for this year, designed to expand market share, drive volume, and improve margins. Combined with our operational excellence, we are laying the groundwork for meaningful financial upside as the year moves on. I will now turn the call over to our CFO, Mansi Khetani, to cover our financials in more detail. Mansi Khetani: Thanks, Rick. As a reminder, please see our earnings press release where we reconcile our non-GAAP results to GAAP. Our principal exclusions are stock-based compensation, amortization of intangible assets, and certain costs related to restructuring and acquisitions. Revenue for the first quarter was $98 million, within our guidance range. Network charging systems at $52 million accounted for 53% of first-quarter revenue. This was almost flat sequentially despite Q1 typically experiencing a seasonal dip and was down 20% year on year. Subscription revenue at $38 million was 39% of total revenue, essentially flat sequentially mostly due to fewer days in Q1 which impacts prorated revenue recognition, and up 14% year on year due to the recurring revenue generated from a higher installed base. Other revenue at $8 million was 8% of total revenue, down 31% sequentially and down 8% year on year. Other includes various revenue items which tend to be lumpy and was significantly lower this quarter primarily as a result of lower one-time project revenue which is recognized based on completion rate. Turning to verticals, which we report from a billing perspective, first-quarter billings percentages were commercial 71%, fleet 13%, residential 12%, and other 3%. From a geographic perspective, North America made up 85% of revenue, and Europe was 15%. Europe was lower than normal, due largely to weakness in Germany. This was partially made up in North America, which was slightly higher compared to last quarter even though the first quarter is typically seasonally lower and despite significant macroeconomic headwinds. Non-GAAP gross margin was 31%, improving by one percentage point sequentially and up seven percentage points year on year. This is attributable to higher margins in both hardware and subscription, as well as subscription revenue growing as a percentage of total revenue. Hardware gross margin increased sequentially despite the impact of incremental tariffs and freight incurred in Q1. Subscription margins reached a record high of 60% on a GAAP basis and were even higher on a non-GAAP basis due to economies of scale and continued optimization of support costs. Based on currently available information, we expect the financial impact of tariffs on our COGS to remain minimal and expect gross margins to continue around the current range and to further improve later in the year. Non-GAAP operating expenses were $57 million, up 9% sequentially and down 15% year on year. As mentioned previously, this quarter's OpEx included the impact of annual raises and investments in certain key areas of the business. We will continue to manage OpEx closely. Non-GAAP adjusted EBITDA loss was $23 million. This compared with a loss of $17 million in the prior quarter and a loss of $36 million in the first quarter of last year. Stock-based compensation was $18 million, up from $15 million in the prior quarter and down from $22 million year on year. Our inventory balance increased by $3 million due to the impact of foreign exchange rates on inventory held by our international subsidiaries. However, we saw a decrease in inventory units across most products as we continue to sell through. We anticipate that inventory balance will reduce gradually throughout the year, helping to free up cash. Speaking of cash, we ended the quarter with $196 million in cash on hand. Q1 tends to be the quarter with the highest cash usage due to the timing of some large annual payments. We will continue to rigorously manage cash, and we have access to a $150 million revolving credit facility which remains undrawn. We have no debt maturities until 2028, and we have existing capacity on our ATM. Turning to guidance, for the second quarter of fiscal 2026, we expect revenue to be $90 million to $100 million. We are guiding with caution due to the continued changes in the macro environment, including tariff uncertainty, as well as our near-term focus on operationalizing our partnership with Eaton. While there is always a possibility of headwinds from deterioration in macro conditions, we expect revenue upside later in the year from the introduction of our new AC hardware that Rick outlined, better performance in Europe, and growth from our new partnership with Eaton. We continue to focus on revenue growth, gross margin expansion, and cost management to achieve our stated goal of being adjusted EBITDA positive in a quarter during fiscal 2026. We will now open the call for questions. At this time, I would like to remind everyone, in order to ask a question, please press star then the number one on your telephone keypad. We request that you limit yourself to one question and one follow-up. We will pause for just a moment to compile the Q&A roster. Our first question comes from the line of Colin Rusch with Oppenheimer. Your line is open. Colin Rusch: Thanks so much, guys. You know, with this Eaton partnership and what you are seeing in terms of the market and the new AC product, can you talk a little bit about the pipeline of activity and how we should be thinking about a return to growth here on the top line for the new systems? Rick Wilmer: Yeah. Thanks, Colin. I think there are a variety of forces at play, some positive, some causing caution. Obviously, the macroeconomic conditions, tariffs, and we are seeing some customers get conservative with spending in cash. There is obviously uncertainty around policies supporting the electrification of transportation, particularly in the US, which I think are also headwinds. On the other hand, we are very excited about our partnership with Eaton. We fully expect that to drive incremental growth, and there is a lot of work to do this quarter in particular to operationalize this relationship. We fully expect to hit our stride and have this, again, fully operationalized as we enter our fiscal Q3. So a variety of factors at play. Colin Rusch: Okay. And then in terms of international expansion, you know, ex-Europe, is Eaton able to help you guys get into some incremental geographies where you have not been operating to date? And how should we think about the potential for the opportunity in Central South America, other parts of North America where you are not maybe fully loaded? You know, it seems like you have got pretty good coverage in the US and Canada, but maybe you are missing something. And then, you know, potentially places like Australia and others where you could see some incremental sales. Rick Wilmer: Yeah. Eaton definitely has the capabilities to do that. At this point in time, we are focused on North America and Europe. We believe with the combined product portfolio, what we have to offer in Europe and North America, we have got plenty of TAM to address in those two geographies. But, again, the possibility definitely exists to penetrate new partnership. Colin Rusch: Thanks so much. And then just a final one on the cadence of the inventory reduction, Mansi. Should we be thinking about that as kind of low single-digit millions, mid-single-digit millions, of inventory consumption on a quarterly basis? Just want to get a better sense of how to get that number on a trajectory basis and what is the right target for you guys in terms of the right inventory that you want to be carrying on an ongoing basis? Mansi Khetani: Yeah. So, you know, obviously, there are a lot of factors that inventory balance will depend on. It depends on the mix of sell-through, the mix of production, etc. So all we can say right now is that we expect gradual reduction with a more meaningful reduction coming in the second half as we see revenue growth. Colin Rusch: Okay. I will hop back in queue. Thanks, guys. Operator: Thank you. Again, if you would like to ask a question, press star one on your telephone keypad. That is all the questions for today. Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 994%* — a market-crushing outperformance compared to 172% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of June 2, 2025 This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
